Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7405 p709
17 June 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Possible £700m of NHS savings identified

Asthma patients

Emergency hospital admissions for asthma patients cost the NHS £64m a year in England

NHS trusts in England have been told how they can both improve patient care and save £700m a year by increasing productivity.

A report (PDF 1.2MB) by the NHS Institute for Innovation and Improvement sets out ways in which primary care trusts and acute trusts can compare how they perform and look for ways of getting nearer the average if they are not doing so well. One of the areas identified for attention is reducing avoidable hospital admissions. The report says that over £120m a year could be saved if there were fewer admissions for conditions such as asthma and angina.

These are included in a list of 19 conditions that can be treated outside hospital and which often lead to multiple admissions each year. They are suggested as targets for community services that could reduce their financial impact on the NHS. Emergency admissions for the 19 conditions cost from £253m a year for chronic obstructive pulmonary disease to £5m for nutritional deficiencies.

Health minister Andy Burnham said: “Cutting the number of avoidable emergency admissions does not mean poorer services. We know patients would rather be treated at home than in hospital and by doing this where it’s appropriate the NHS can save money as well as improve patient care.”

At the same time, the NHS Confederation published its own report saying that NHS trust chief executives believe that they have to increase productivity and cut waste before they can ask the Government for more money.

The confederation’s “Lean thinking for the NHS” report (PDF 470K) sets out ways of redesigning services to strip out unnecessary activities and paperwork. For example, using this technique, Bolton Hospitals NHS Trust has been able to cut its death rate for patients having hip operations by a third in nine months.

Back to Top


©The Pharmaceutical Journal